Suplatast tosilate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Suplatast tosilate
Suplatast tosilate.png
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.220.132
Chemical and physical data
Formula C23H33NO7S2
Molar mass 499.64 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Suplatast tosilate (INN) is a Th2 cytokine inhibitor[1] which is used as an antiallergic drug. It has been suggested and applied in the treatment of Kimura's disease a few times.[2][3]

References[edit]

  1. ^ Tamaoki J, Kondo M, Sakai N, et al. (July 2000). "Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group". Lancet. 356 (9226): 273–8. PMID 11071181. doi:10.1016/S0140-6736(00)02501-0. 
  2. ^ Ueda T, Arai S, Amoh Y, Katsuoka K (2011). "Kimura's disease treated with suplatast tosilate and loratadine". European Journal of Dermatology. 21 (6): 1020–1. PMID 21914581. doi:10.1684/ejd.2011.1539. 
  3. ^ Tsukagoshi H, Nagashima M, Horie T, et al. (December 1998). "Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T)". Internal Medicine. 37 (12): 1064–7. PMID 9932643. doi:10.2169/internalmedicine.37.1064. 

Further reading[edit]

  • Taniguchi H, Togawa M, Ohwada K, et al. (December 1996). "Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs". European Journal of Pharmacology. 318 (2-3): 447–54. PMID 9016937. doi:10.1016/S0014-2999(96)00810-2. 
  • Sano Y (December 1996). "[Anti-inflammatory drugs for the treatment of bronchial hyperresponsiveness]". Nihon Kyōbu Shikkan Gakkai Zasshi (in Japanese). 34 Suppl: 48–53. PMID 9216184.